自体造血干细胞移植及CAR-T细胞疗法在复发/难治弥漫性大B细胞淋巴瘤中的应用进展

杨漾; 张义成

doi:10.13201/j.issn.1004-2806.2023.09.003

自体造血干细胞移植及CAR-T细胞疗法在复发/难治弥漫性大B细胞淋巴瘤中的应用进展

杨漾¹,
张义成^1, ,

- 华中科技大学同济医学院附属同济医院血液内科(武汉，430030)
基金项目:
国家自然科学基金(No：81973998)

详细信息

作者简介:
张义成，教授，主任医师，博士生导师。华中科技大学同济医学院附属同济医院血液科主任，湖北省血液免疫细胞治疗研究中心主任，中华血液学会造血干细胞移植学组委员，中国抗癌协会血液肿瘤专业委员会常委，湖北省抗癌协会血液肿瘤专业委员会主任委员，美国血液学会(ASH)会员

通讯作者: 张义成，E-mail：yczhang@tjh.tjmu.edu.cn

中图分类号: R457.7

收稿日期: 2023-08-06

刊出日期: 2023-09-01

Advancements in the application of autologous hematopoietic stem cell transplantation and CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma

YANG Yang¹,
ZHANG Yicheng^1, ,

- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

More Information

Corresponding author: ZHANG Yicheng, E-mail: yczhang@tjh.tjmu.edu.cn

Received Date: 06 August 2023

Publish Date: 01 September 2023

摘要

摘要: 弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma，DLBCL)是最常见的侵袭性淋巴瘤亚型。尽管约60%~65%的患者可以通过化疗和免疫疗法实现治愈，但对于那些疾病难以控制或复发的患者，预后往往不佳。目前适合移植的复发/难治DLBCL患者还在接受强化的救治方案，然后接受高剂量化疗和自体干细胞移植，但仅能治愈数量有限的患者。新的治疗方式如CAR-T细胞疗法可能在未来取代传统疗法，尤其对于挽救性化疗不够敏感的患者。此外，自体干细胞移植续贯CAR-T细胞疗法可能进一步提升如TP53突变及中枢神经系统淋巴瘤等高危类型淋巴瘤的疗效。
- 自体造血干细胞移植 /
- CAR-T细胞疗法 /
- 弥漫性大B细胞淋巴瘤
Abstract: Diffuse large B-cell lymphoma(DLBCL)is the most common aggressive subtype of lymphoma. While approximately 60%-65% of patients can achieve cure through chemotherapy and immunotherapy, the prognosis is often poor for those with disease refractory to control or relapse. Until now, eligible transplant recipients with relapsed or refractory DLBCL undergo intensified salvage regimens followed by high-dose chemotherapy and autologous stem cell transplantation, providing curative benefit to only a limited number of patients. Novel treatment modalities like CAR-T cell therapy may potentially replace conventional approaches in the future, particularly for patients less responsive to salvage chemotherapy. Furthermore, the continuum of autologous stem cell transplantation and CAR-T cell therapy might further enhance the therapeutic efficacy for high-risk lymphoma types such as those with TP53 mutations and central nervous system involvement.
- autologous hematopoietic stem cell transplantation /
- CAR-T cell therapy /
- diffuse large B-cell lymphoma

HTML全文

参考文献(36)

[1]	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
[2]	Frontzek F, Karsten I, Schmitz N, et al. Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma[J]. Ther Adv Hematol, 2022, 13: 20406207221103321.
[3]	Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: A Phase Ⅲ Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma[J]. J Clin Oncol, 2021, 39(12): 1317-1328. doi: 10.1200/JCO.20.01366
[4]	Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma(REMoDL-B): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2019, 20(5): 649-662. doi: 10.1016/S1470-2045(18)30935-5
[5]	Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2022, 386(4): 351-363. doi: 10.1056/NEJMoa2115304
[6]	Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J]. Blood, 2010, 116(12): 2040-2045. doi: 10.1182/blood-2010-03-276246
[7]	Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma[J]. N Engl J Med, 1987, 316(24): 1493-1498. doi: 10.1056/NEJM198706113162401
[8]	Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma[J]. N Engl J Med, 1995, 333(23): 1540-1545. doi: 10.1056/NEJM199512073332305
[9]	Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era[J]. J Clin Oncol, 2010, 28(27): 4184-4190. doi: 10.1200/JCO.2010.28.1618
[10]	Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY. 12[J]. J Clin Oncol, 2014, 32(31): 3490-3496. doi: 10.1200/JCO.2013.53.9593
[11]	He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma[J]. Leukemia, 2021, 35(8): 2151-2165. doi: 10.1038/s41375-021-01285-3
[12]	Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2019, 380(1): 45-56. doi: 10.1056/NEJMoa1804980
[13]	Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma[J]. N Engl J Med, 2017, 377(26): 2531-2534. doi: 10.1056/NEJMoa1707447
[14]	Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396(10254): 839-852. doi: 10.1016/S0140-6736(20)31366-0
[15]	Heymach J, Krilov L, Alberg A, et al. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology[J]. J Clin Oncol, 2018, 36(10): 1020-1044. doi: 10.1200/JCO.2017.77.0446
[16]	June CH, O'Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer[J]. Science, 2018, 359(6382): 1361-1365. doi: 10.1126/science.aar6711
[17]	Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(1): 31-42. doi: 10.1016/S1470-2045(18)30864-7
[18]	Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma[J]. N Engl J Med, 2022, 386(7): 640-654. doi: 10.1056/NEJMoa2116133
[19]	Pinnix CC, Gunther JR, Dabaja BS, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma[J]. Blood Adv, 2020, 4(13): 2871-2883. doi: 10.1182/bloodadvances.2020001837
[20]	Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. doi: 10.1016/j.bbmt.2018.12.758
[21]	Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62. doi: 10.1038/nrclinonc.2017.148
[22]	Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality[J]. Blood Adv, 2020, 4(13): 3024-3033. doi: 10.1182/bloodadvances.2020001972
[23]	Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma[J]. N Engl J Med, 2022, 386(7): 629-639. doi: 10.1056/NEJMoa2116596
[24]	Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma(TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial[J]. Lancet, 2022, 399(10343): 2294-2308. doi: 10.1016/S0140-6736(22)00662-6
[25]	Li C, Zhang Y, Zhang C, et al. Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma[J]. JCI Insight, 2019, 5(17): e130195.
[26]	Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas[J]. N Engl J Med, 2017, 377(26): 2545-2554. doi: 10.1056/NEJMoa1708566
[27]	Kebriaei P, Singh H, Huls MH, et al. Phase Ⅰ trials using Sleeping Beauty to generate CD19-specific CAR T cells[J]. J Clin Invest, 2016, 126(9): 3363-3376. doi: 10.1172/JCI86721
[28]	Wang X, Popplewell LL, Wagner JR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL[J]. Blood, 2016, 127(24): 2980-2990. doi: 10.1182/blood-2015-12-686725
[29]	Cao Y, Xiao Y, Wang N, et al. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas[J]. Transplant Cell Ther, 2021, 27(11): 910.e1-910.e11.
[30]	Wei J, Xiao M, Mao Z, et al. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT[J]. Signal Transduct Target Ther, 2022, 7(1): 101. doi: 10.1038/s41392-022-00924-0
[31]	Wu J, Meng F, Cao Y, et al. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma[J]. Blood Cancer J, 2021, 11(7): 131. doi: 10.1038/s41408-021-00523-2
[32]	Xue F, Zheng P, Liu R, et al. The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma[J]. J Oncol, 2022, 2022: 2900310.
[33]	Chiappella A, Diop F, Agostinelli C, et al. Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial[J]. Br J Haematol, 2022, 196(5): 1184-1193. doi: 10.1111/bjh.17971
[34]	Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma(DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2017, 18(8): 1076-1088. doi: 10.1016/S1470-2045(17)30444-8
[35]	Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma[J]. Cancer, 2017, 123(22): 4314-4324. doi: 10.1002/cncr.30965
[36]	El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma[J]. Eur J Cancer, 2018, 93: 57-68. doi: 10.1016/j.ejca.2018.01.073